A New Neurotech Startup Launches to Rival Sam Altman’s Merge Labs

Bridge Neurotech launched with $13.5 million in funding to develop a wearable, ultrasound-based brain-computer interface, positioning it as a noninvasive alternative to surgically implanted systems. Its initial observational study will enroll healthy adults and people who have undergone skull surgery; the company plans to use predictive AI to address ultrasound’s few-seconds lag in measuring neural activity. The approach remains early, with bone-related imaging challenges and uncertain suitability for fast-paced tasks.

Analysis

The investable angle is component-level optionality, not a near-term BCI market: Bridge’s use of Butterfly Network (BFLY) silicon probes creates a possible design-win pathway, but the current study is observational and does not establish a commercial product, repeat orders, or meaningful revenue for BFLY. Treat this as an R&D validation signal, not an earnings catalyst. The key technical hurdle is whether ultrasound can obtain useful signals through intact skull; even if it can, blood-flow-based decoding is inherently slower than direct neural recording. Predictive AI may compensate for some lag, but would need to demonstrate reliable performance rather than merely improve a lab metric. This limits the initial addressable use cases and makes rapid motor control a harder target than slower or lower-stakes applications.

Over the next 1–3 months, watch for protocol/results detail from Bridge’s volunteer study and any confirmation that BFLY is a supplier beyond prototype equipment. Over 6–18 months, reproducible through-skull performance and regulatory/clinical progression would matter more than venture funding or founder credentials. Surgical implant developers retain an advantage in high-bandwidth applications if noninvasive systems cannot overcome skull attenuation and latency. Conversely, a safe wearable could broaden use cases and expand the category rather than simply displace implants. The contrarian point: headline enthusiasm may overvalue the size of the eventual consumer market while underestimating the technical and clinical validation runway. No direct ABNB read-through: its mention is only as a prior General Catalyst investment.

Key Decisions for Investors

• Do not trade ABNB on this story; the company has no disclosed operating or financial exposure to the BCI development.
• Keep BFLY on a catalyst watchlist, not as a fundamental buy signal. Reassess only if Bridge confirms commercial supply terms, repeatable probe demand, or a material contribution to BFLY guidance; current financial exposure is unquantified.
• Avoid treating private Bridge or Merge funding as evidence of clinical viability. Track study results for intact-skull signal quality, decoding accuracy, latency, and performance across users and tasks.
• Falsify the noninvasive-ultrasound thesis if Bridge’s studies require a skull window, fail to show useful decoding through intact skull, or cannot reduce latency for intended applications; such outcomes preserve the advantage of implanted systems.